Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,992,688
  • Shares Outstanding, K 48,005
  • Annual Sales, $ 186,370 K
  • Annual Income, $ -163,420 K
  • EBIT $ -96 M
  • EBITDA $ -84 M
  • 60-Month Beta 1.20
  • Price/Sales 10.59
  • Price/Cash Flow N/A
  • Price/Book 8.46

Options Overview Details

View History
  • Implied Volatility 72.99% ( +6.83%)
  • Historical Volatility 42.63%
  • IV Percentile 62%
  • IV Rank 56.65%
  • IV High 104.11% on 03/12/24
  • IV Low 32.33% on 05/15/24
  • Put/Call Vol Ratio 0.57
  • Today's Volume 44
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 7,374
  • Open Int (30-Day) 7,165

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate -0.24
  • Low Estimate -0.41
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +53.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.03 +3.70%
on 12/18/24
47.08 -11.83%
on 11/29/24
-2.18 (-4.99%)
since 11/20/24
3-Month
37.51 +10.66%
on 10/09/24
48.89 -15.10%
on 11/14/24
+2.55 (+6.55%)
since 09/20/24
52-Week
23.14 +79.39%
on 04/25/24
48.89 -15.10%
on 11/14/24
+10.72 (+34.82%)
since 12/20/23

Most Recent Stories

More News
Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally...

IMCR : 28.33 (-0.33%)
MIRM : 41.51 (+0.92%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...

IMCR : 28.33 (-0.33%)
MIRM : 41.51 (+0.92%)
CSTL : 27.53 (+1.62%)
ANIP : 53.35 (-1.68%)
United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023

Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall

VLO : 118.59 (-0.29%)
ADBE : 447.17 (+2.24%)
MIRM : 41.51 (+0.92%)
DOOR : 132.84 (+0.05%)
NIO : 4.54 (+3.18%)
ILMN : 136.02 (+1.51%)
Why Shares of Travere Therapeutics Are Slumping Thursday

A mixed trial could hurt a kidney drug's chances of full approval.

MIRM : 41.51 (+0.92%)
TVTX : 17.18 (-1.26%)
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

MIRM : 41.51 (+0.92%)
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...

MIRM : 41.51 (+0.92%)
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...

MIRM : 41.51 (+0.92%)
American Airlines, Emerson Electric fall; Triton, Chart rise

Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise

MIRM : 41.51 (+0.92%)
TRTN : 79.55 (-4.10%)
EMR : 124.09 (+1.42%)
TH.TO : 2.50 (+4.17%)
NATI : 59.98 (unch)
NCMI : 6.72 (-0.30%)
GTLS : 184.83 (+2.23%)
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior...

MIRM : 41.51 (+0.92%)
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023.

MIRM : 41.51 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 44.98
2nd Resistance Point 43.92
1st Resistance Point 42.71
Last Price 41.51
1st Support Level 40.44
2nd Support Level 39.38
3rd Support Level 38.17

See More

52-Week High 48.89
Last Price 41.51
Fibonacci 61.8% 39.05
Fibonacci 50% 36.01
Fibonacci 38.2% 32.98
52-Week Low 23.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar